South Delhi Pharma, New Delhi, India
VISTOGARD (uridine triacetate) oral granules.
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email firstname.lastname@example.org to discuss.
VISTOGARD is a prescription medicine. VISTOGARD used for emergency treatment of adults and children.
VISTOGARD® is a pyrimidine analog indicated for the emergency treatment of adult and pediatric patients:
• following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or
• who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or earlyonset, unusually severe adverse reactions (e.g., gastrointestinal
toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.
DOSAGE FORMS & STRENGTHS
Oral granules: 10 gram packets
Manufactured By: Wellstat Therapeutics Corporation
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “VISTOGARD ® (uridine triacetate) oral granules” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Uridine triacetate (INN), formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine used:
- in the treatment of hereditary orotic aciduria
- to treat people following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).